• 1
    Tan RS, Butterworth CM, McLaughlin H, Malka S, Samman PD. Mycosis fungoides–a disease of antigen persistence. Br J Dermatol. 1974; 91: 607-616.
  • 2
    Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 116: 767-771.
  • 3
    Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996; 107: 373-376.
  • 4
    Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005; 124: 741-750.
  • 5
    Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997; 89: 32-40.
  • 6
    Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003; 101: 2132-2136.
  • 7
    Magro CM, Crowson AN. Drugs with antihistaminic properties as a cause of atypical cutaneous lymphoid hyperplasia. J Am Acad Dermatol. 1995; 32: 419-428.
  • 8
    Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol. 1991; 24( 2 Pt 1): 216-220.
  • 9
    Brady SP, Magro CM, Diaz-Cano SJ, Wolfe HJ. Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR/DGGE. Hum Pathol. 1999; 30: 130-136.
  • 10
    Fischmann AB, Bunn PA Jr, Guccion JG, Matthews MJ, Minna JD. Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome. Cancer Treat Rep. 1979; 63: 591-596.
  • 11
    National Heart, Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: NHLBI; 2004.
  • 12
    Pimpinelli N, Olsen EA, Santucci M, et al; International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol. 2005; 53: 1053-1063.
  • 13
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245.
  • 14
    Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003; 37: 1774-1778.
  • 15
    Mitchell AA. Patterns of Medication Use in The United States 2005: A Report from the Slone Survey. Accessed March 22, 2012.
  • 16
    Ruscin JM, Page RL2nd, Scott J. Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature. Am J Geriatr Pharmacother. 2006; 4: 325-329.
  • 17
    Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J. 2006; 12: 1.
  • 18
    Pétavy-Catala C, Martin L, Fontès V, Lorette G, Vaillant L. Hydrochlorothiazide-induced acute generalized exanthematous pustulosis. Acta Derm Venereol. 2001; 81: 209.
  • 19
    Burckhardt W, Sutter T. Photoallergic drug exanthema caused by hydrochlorothiazide [in German]. Z Haut Geschlechtskr. 1963; 34: 105-108.
  • 20
    Grunwald MH, Halevy S, Livni E. Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test. Isr J Med Sci. 1989; 25: 572-574.
  • 21
    Vega F, Luthra R, Medeiros LJ, Dunmire V, Lee SJ, Duvic M, Jones D. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002; 100: 3369-3373.
  • 22
    Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007; 204: 2449-2460.
  • 23
    Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004; 44: 398-404.
  • 24
    Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology, and Therapeutics for Physicians and Medical Students. 3rd ed. New York, NY: Macmillan; 1965.
  • 25
    Han KD, Bark KM, Heo EP, Lee JK, Kang JS, Kim TH. Increased phototoxicity of hydrochlorothiazide by photodegradation. Photodermatol Photoimmunol Photomed. 2000; 16: 121-124.
  • 26
    Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005; 18: 1077-1083.
  • 27
    Monroe JR. A common cause of photodistributed rash. JAAPA. 2006; 19: 53.
  • 28
    Westman E, Lundberg K, Erlandsson Harris H. Arthritogenicity of collagen type II is increased by chlorination. Clin Exp Immunol. 2006; 145: 339-345.